In the past decade, an explosion of new treatments, including those with novel mode of actions, have revolutionised the psoriasis armamentarium. How many patients can expect to benefit from these new treatments? What are the ongoing unmet needs among patients with psoriasis? How have the new therapies influenced the current treatment guidelines and what can we expect in the near future? We interviewed Professor Andrew Blauvelt and Professor Ulrich Mrowietz at EADV 2019 and Professor Paolo Gisondi and Professor Rolland Gyulai at EADV 2018 to address these topics and much more.
Expert insights from EADV 2019 and the evolution of 'psoriasis-targeted' treatments
At the EADV Congress 2019 we interviewed psoriasis key opinion leaders Professors Andrew Blauvelt and Ulrich Mrowietz about their experience and opinions. They discuss the challenges in treating psoriasis and some of the principles in selecting treatment. See the below video selections.
Expert insights from EADV 2018